in gynecologic malignancies, of 1.9 to 4.3%, and commonly occurring in endometrial and ovarian malignancies. Renal tumors coexisting with primary cervical cancer are mostly metastatic tumors, and at present, no case of cervical carcinoma metachronous with renal cell carcinoma has been reported on literature.

This is a case of Papillary Squamous Cell Carcinoma of the cervix who developed a metachronous Clear Cell Renal Cell Carcinoma. Several months after the diagnosis of cervical cancer, she presented with an abdominal mass and signs of uremia secondary to obstructive uropathy. She underwent radical nephrectomy with contralateral percutaneous nephrostomy. Definitive plan for the cervical mass is concurrent chemotherapy and radiotherapy, depending on the improvement in renal function.

Currently, there are no clearly established guidelines in managing metachronous cervical and renal masses, and this presents a unique opportunity to document this case, and study its implications on management and prognosis.

**IGCS20_1382**

**GLS-010 (Zimberelimab), A Novel Fully Human Anti-PD-1 MAB in Chinese Patients with Recurrent/Metastatic Cervical Cancer: Results from a Multicenter, Open-Label, Single-Arm Phase II Trial**

X Wu*, 1L Xia, 2Q Zhou, 3J Zhu, 4K Wang, 5J Chen, 6Y Huang, 7G Kurb, 8B Chang, 8W Zhao, 9X Wang, 10Y Yang, 11Z Liu, 12X Luo, 13G Lou, 14C Wang, 15J Wang, 16H Meng. 
1Department of gynecologic oncology, Fudan University Shanghai Cancer Center, China; 2Changhai Cancer Hospital, China; 3Zhejiang Cancer Hospital, China; 4Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, China; 5Hubei cancer hospital, China; 6Cancer hospital affiliated to xinjiang medical university, China; 7The First Affiliated Hospital of Henan University of Science and Technology, China; 8The first affiliated hospital of university of science and technology of China, China; 9The Affiliated Hospital of Xuzhou Medical University, China; 10Guizhou Cancer Hospital, China; 11Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China; 12Linyang Central Hospital, China; 13Department of Gynecology Oncology, Haibin Medical University Cancer Hospital, China; 14The 4th Department of Gynecology, Cancer Hospital of China Medical University, LiaoNing Cancer Hospital and Institute, China; 15Hunan Cancer Hospital, Changsha, China; 16Guangzhou Glory Biosciences Co., Ltd, China

**Conclusion** GLS-010 (Zimberelimab) showed encouraging therapeutic activity and manageable safety profile in Chinese recurrent or metastatic cervical cancer patients. This study is still ongoing, and we are looking forward to further results.

**IGCS20_1383**

**Phase 3 Trial of Tumor Treating Fields Concomitant with Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: ENGOT-OV50/GOG-329/INNOVATE-3**

1Vergote*, 2V Salutari, 3D Cibula, 4J Korach, 5EP Samartzi, 6J Sehouli, 7R Fossati, 8AG Martin, 9T Habaliuk, 10B Slomovitz, 11R Coleman, 12B Monk, 13P Thaker, 14D O'Malley, 1Leuven Cancer Institute, Belgium; 2Foundation Policlinico Universitario Agostino Gemelli, Italy; 3Charles University Hospital, Czech Republic; 4Chaim Sheba Medical Center, Israel; 5University Hospital Zürich, Switzerland; 6Chanté Frauenklinik, Germany; 7IRCCS-Istituto di Ricerca Farmacologica, Italy; 8Clinical Universidad de Navarra, Spain; 9Medical University Innsbruck, Austria; 10University of Miami, Sylvester Comprehensive Cancer Center, USA; 11MD Anderson Cancer Center, USA; 12University of Arizona College of Medicine, USA; 13Washington University Gynecological Oncology, USA; 14Ohio State University Comprehensive Cancer Center, USA

**Abstract** GLS-010 (Zimberelimab) is a novel fully human anti-PD-1 monoclonal antibody developed on the OMT transgenic rat platform, exhibiting good tolerance and preliminary efficacy in previous phase I study.

**Methods** In this open-label phase II clinical trial (NCT03972722), PD-L1 positive (combined positive score (CPS) ≥1) patients with recurrent or metastatic cervical cancer who had received one or more lines of chemotherapy were enrolled. All patients received GLS-010 240 mg every 2 weeks. Objective response was evaluated by RECIST v1.1. AEs were graded by NCI-CTCAE, version 4.03.

**Results** A total of 45 patients with recurrent or metastatic cervical cancer were enrolled. As of April 2, 2020, of 41 evaluable patients, 11 achieved an objective response by investigator assessment with an ORR of 26.3% and a DCR of 53.66%. After a median follow-up time of 5.2 months (range: 1.6–9.7), 18 patients still remained on treatment and 27 of them discontinued treatment due to progressive disease or adverse events. The Median DOR had not been reached yet. 36 of 45 (80.00%) patients experienced one or more treatment-related adverse events (TRAEs), most of which were Grade 1 or 2. 11 patients discontinued treatment due to adverse event.

**Conclusion** GLS-010 (Zimberelimab) showed encouraging therapeutic activity and manageable safety profile in Chinese recurrent or metastatic cervical cancer patients. This study is still ongoing, and we are looking forward to further results.